Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
SAN FRANCISCO, Nov. 01, 2016 -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that FibroGen will report third quarter 2016 financial results on Tuesday, November 8, 2016, after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast will be available on the investor section of the company’s website for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use the passcode 43661114#.
Dial-In Information
Live (US/Canada): (888) 771-4371
Live (International): (847) 585-4405
Passcode: 43661114
About FibroGen
FibroGen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company utilizes its extensive experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate development programs in multiple therapeutic areas. Its most advanced product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases, or HIF-PHs, in Phase 3 clinical development for the treatment of anemia in CKD. A second product candidate, FG-3019, or pamrevlumab, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy. For more information please visit: www.fibrogen.com.
Contact Karen L. Bergman Vice President, Investor Relations and Corporate Communications FibroGen, Inc. 415-978-1433 [email protected]
